ObjectivesTo assess the association between learning disability and risk of hospitalisation and mortality from
COVID-19 MESHD in England among adults and children.
DesignWorking on behalf of
NHS England MESHD, two cohort studies using patient-level data for >17 million people from primary care electronic health records were linked with death data from the Office for National Statistics and hospitalization data from NHS Secondary Uses Service using the OpenSAFELY platform.
SettingGeneral practices in England which use TPP software.
ParticipantsParticipants were males and females, aged up to 105 years, from two cohorts: (1)
wave 1 HGNC, registered with a TPP practice as of 1st March 2020 and followed until 31st August, 2020; (2)
wave 2 HGNC registered 1st September 2020 and followed until 31st December 2020 (for admissions) or 8th February 2021 (for deaths). The main exposure group was people included on a general practice learning disability register (LDR), with a subgroup of people classified as having profound or severe
learning disability MESHD. We also identified patients with Down syndrome and
cerebral palsy MESHD (whether or not on the learning disability register).
Main outcome measures(i)
COVID-19 MESHD related death, (ii)
COVID-19 MESHD related hospitalisation. Non-
COVID-19 MESHD related
death MESHD was also explored.
ResultsIn
wave 1 HGNC, of 14,301,415 included individuals aged 16 and over, 90,095 (0.63%) were identified as being on the LDR. 30,173 COVID-related hospital admissions, 13,919
COVID-19 MESHD related deaths and 69,803 non-COVID
deaths MESHD occurred; of which 538 (1.8%), 221 (1.6%) and 596 (0.85%) were among individuals on the LDR, respectively. In
wave 2 HGNC, 27,611 COVID-related hospital admissions, 17,933
COVID-19 MESHD related deaths and 54,171 non-COVID
deaths MESHD occurred; of which 383 (1.4%), 260 (1.4%) and 470 (0.87%) were among individuals on the LDR.
Wave 1 HGNC hazard ratios for individuals on the LDR, adjusted for age, sex, ethnicity and geographical location, were 5.3 (95% confidence interval (CI) 4.9, 5.8) for
COVID-19 MESHD related hospital admissions and 8.2 (95% CI: 7.1, 9.4) for
COVID-19 MESHD related death.
Wave 2 HGNC produced similar estimates. Associations were stronger among those classed as severe-profound and among those in residential care. Down syndrome and
cerebral palsy MESHD were associated with increased hazard of both events in both waves; Down syndrome to a much greater extent. Hazards of non-
COVID-19 MESHD related death followed similar patterns with weaker associations.
ConclusionsPeople with
learning disabilities MESHD have markedly increased risks of hospitalisation and mortality from
COVID-19 MESHD. This raised risk is over and above that seen for non-COVID causes of
death MESHD. Ensuring prompt access to
Covid-19 MESHD testing and health care and consideration of prioritisation for
COVID-19 MESHD vaccination and other targeted preventive measures are warranted.